Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA, CMS Reviewers Appraise Cost Effectiveness; ICD Decision Scrutinized

This article was originally published in The Gray Sheet

Executive Summary

Cost-effectiveness analyses represent an opportunity for greater FDA/CMS collaboration when the agencies review device trials for approval or reimbursement decisions, according to FDA Office of Device Evaluation Director Dan Schultz

You may also be interested in...



Health Affairs Study Deflects New Tech Cost Critics; JEC Report Forthcoming

An article in the 1July/August issue of Health Affairs cites economic data from FDA Commissioner Mark McClellan to argue that thwarted access to new medical technologies among the uninsured yields $1.1 bil. in lost annual net benefits

Health Affairs Study Deflects New Tech Cost Critics; JEC Report Forthcoming

An article in the 1July/August issue of Health Affairs cites economic data from FDA Commissioner Mark McClellan to argue that thwarted access to new medical technologies among the uninsured yields $1.1 bil. in lost annual net benefits

Generalizability Of Prophylactic ICD Benefits Questioned By CMS, Panelists

CMS' reliance on the precise wording of Guidant's original national coverage determination request for expanded ICD use suggests the need for companies to tailor their requests to avoid overly broad interpretations

Related Content

UsernamePublicRestriction

Register

MT017964

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel